Evidence map›Paper›PMID 35538733›Full record

ArticleOrthopaedic surgery2022

Correlation between Patient-Derived Xenograft Modeling and Prognosis in Osteosarcoma.

Mengxiong Sun, Zongyi Wang, Wei Sun, Ming Chen, Xiaojun Ma, Jiakang Shen, Zeze Fu, Dongqing Zuo, Gangyang Wang, Hongsheng Wang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Orthopaedic surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Drug sensitivity testing of patient-derived bone sarcomas identifies selective kinase inhibitors for patients with refractory disease.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. MFNG is an independent prognostic marker for osteosarcoma.European journal of medical research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mengxiong Sun *Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-5514-7160
Zongyi Wang *Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Wei SunDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Ming ChenDepartment of Orthopaedics, Qingpu Branch of Zhongshan Hospital Affiliated with Fudan University, Shanghai, China.
Xiaojun MaDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Jiakang ShenDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Zeze FuDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Dongqing ZuoDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Gangyang WangDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Hongsheng WangDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Chongren WangDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Fei YinDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Zhuoying WangDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Chuanying ZhangDepartment of Orthopaedics, Renhe Hospital, Shanghai, China.
Yingqi HuaDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Zhengdong CaiDepartment of Orthopaedics, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-3246-7209

Funding

Medical Intersection Project of Shanghai Jiaotong University YG2017QN28National Natural Science Foundation of China 81772859National Natural Science Foundation of China 81802985National Natural Science Foundation of China 81972512National Natural Science Foundation of China 82102763Qingpu District Science and Technology Development Fund project QKY2019-10Shanghai Sailing Program 21YF1436500
6 · The paper itself

Abstract

objectiveTo retrospectively analyze and compare the relationship between the success rate of patient-derived xenograft (PDX) modeling of osteosarcoma and prognosis (3-year overall survival rate and disease-free survival rate) and incidence of lung metastasis.

methodsThe sample group consisted of 57 osteosarcoma patients with definite pathological diagnoses from Shanghai General Hospital from 2015-2017. PDX models in 57 patients were analyzed by retrospective analyses. Among the patients currently inoculated, 20 were tumorigenic in the PDX model, and 37 were nontumorigenic. According to the tumorigenicity of PDXs, the corresponding osteosarcoma patients were divided into two groups. The effects of clinically related indicators on the model were retrospectively compared. The patients were followed, and the 3-year survival, 3-year disease-free survival (DFS), and lung metastasis rates were collected. The relationship between the modeling success and patient prognosis was investigated.

resultsIn the chemotherapy-treated group, the PDX modeling success rate was 17.4%, and in the nonchemotherapy group, the success rate was 47.1%. The success of PDX modeling was related to whether patients received chemotherapy. The success rate of PDX modeling is significantly reduced after receiving chemotherapy. The 3-year overall survival rate of the PDX-grafted group was 49.23%, and that of the PDX-nongrafted group was 65.71%. There was a significant difference between the two groups, showing a strong negative correlation between the 3-year survival rate and the success rate of the PDX model. The 3-year disease-free survival rate of the PDX-grafted group was 29.54%. The 3-year DFS of the PDX-nongrafted group was 50.34%. There was a significant difference between the two groups. Lower grafted rates indicate a higher DFS rate. The incidence of lung metastasis in the PDX-grafted group was 32.4%, and that in the nongrafted group was 13.1%. There was a significant difference between the two groups. The successful establishment of the PDX model indicates that patients are more likely to have lung metastases.

conclusionsThe success of PDX modeling often indicates poor prognosis (low 3-year overall survival rate and disease-free survival rate) and a greater possibility of lung metastasis. Therefore, PDX modeling in osteosarcoma patients can accurately predict the prognosis of patients and the risk of lung metastasis in advance to help us develop better therapeutic strategies.

Indexed as

Bone NeoplasmsLung NeoplasmsOsteosarcomaAnimalsChinaDisease Models, AnimalHeterograftsHumansPrognosisRetrospective StudiesChemotherapyOsteosarcomaPatient-derived xenograftPrognosis

Identifiers

PMID35538733
PMCPMC9163969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.